- Endoxifen
-
- $65.00 / 10mg
-
2025-05-01
- CAS:110025-28-0
- Min. Order:
- Purity: 99.66%
- Supply Ability: 10g
|
| | N-Desmethyl-4-hydroxy Tamoxifen (approx. 1:1 E/Z Mixture) Basic information |
| | N-Desmethyl-4-hydroxy Tamoxifen (approx. 1:1 E/Z Mixture) Chemical Properties |
| Melting point | 63-72°C | | Boiling point | 519.3±50.0 °C(Predicted) | | density | 1.099±0.06 g/cm3(Predicted) | | storage temp. | -20°C Freezer | | solubility | Chloroform, Dichloromethane, DMSO, Methanol | | form | Solid | | pka | 9.38±0.15(Predicted) | | color | Light Brown to Light Purple |
| | N-Desmethyl-4-hydroxy Tamoxifen (approx. 1:1 E/Z Mixture) Usage And Synthesis |
| Chemical Properties | Brown Foam | | Uses | A novel active metabolite of the anti-cancer drug Tamoxifen (T006000). It showed potent ER binding property, blocked estrogen stimulated growth of breast cancer cell and half maximal inhibition of estrogen responsive gene expression in ER pos. human breast cancer cell line. | | Uses | A novel active metabolite of the anti-cancer drug Tamoxifen. It showed potent ER binding property, blocked estrogen stimulated growth of breast cancer cell and half maximal inhibition of estrogen responsive gene expression in ER pos. human breast ca | | in vivo | Orally administered Endoxifen is rapidly absorbed and systemically available when tested in female rats. The Endoxifen-treated rats show 787% higher exposure (AUC0–∞) and 1,500% higher concentration (Cmax) levels of Endoxifen when compared with Tamoxifen. Oral Endoxifen administration once a day for 28 consecutive days at dosages 2, 4, and 8 mg/kg proves safe and results in progressive inhibition of the growth of the human mammary tumor xenografts in female mice[2]. | | IC 50 | Aromatase; ERα | | storage | Store at +4°C |
| | N-Desmethyl-4-hydroxy Tamoxifen (approx. 1:1 E/Z Mixture) Preparation Products And Raw materials |
|